NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience

BACKGROUND AND PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) remains one of the leading causes of cancer-related deaths in the world. For patients with PDAC who are not eligible for surgery, radiation therapy improves local disease control, yet safely delivering therapeutic doses of radiation rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagley, Alexander F., Ludmir, Ethan B., Maitra, Anirban, Minsky, Bruce D., Li Smith, Grace, Das, Prajnan, Koong, Albert C., Holliday, Emma B., Taniguchi, Cullen M., Katz, Matthew H.G., Tamm, Eric P., Wolff, Robert A., Overman, Michael J., Patel, Shivani, Kim, Michael P., Tzeng, Ching-Wei D., Ikoma, Naruhiko, Bhutani, Manoop S., Koay, Eugene J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783106/
https://www.ncbi.nlm.nih.gov/pubmed/35097226
http://dx.doi.org/10.1016/j.ctro.2021.12.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783106/
https://www.ncbi.nlm.nih.gov/pubmed/35097226
http://dx.doi.org/10.1016/j.ctro.2021.12.012

Ejemplares similares